Boston Scientific is reaping the rewards from the energised PFA market opportunity in atrial fibrillation treatment.

Farapulse, Boston Scientific’s pulsed field ablation product, fueled year-over-year growth of nearly 171% in the fourth ...

Boston Scientific apparently knows a good bet when it sees one. | That includes treating more than 200,000 patients with the irregular heartbeat known as atrial fibrillation—and the sum more than ...

The company states: “Boston Scientific (BSX) announced data supporting the use of the FARAPULSE Pulsed Field Ablation System* and the WATCHMAN FLX Left Atrial Appendage Closure Device ...

as the narrow-moat-rated Boston Scientific largely met our full-year expectations, and our 2025 projections remain bounded by management's outlook. We expect the Farapulse franchise for atrial ...

Boston Scientific (NYSE: BSX) shares ticked up slightly before hours today on fourth-quarter results that beat the consensus ...

Potential supply chain challenges were addressed, with management affirming adequate capacity to meet growing FARAPULSE demand. Boston Scientific delivered another strong quarter, exceeding ...

Medical device maker Boston Scientific forecast annual profit above Wall Street estimates on Wednesday, banking on steady demand for its heart devices.

Boston Scientific, with approximately 10,000 employees in Minnesota, reported a fourth-quarter adjusted net profit of $1 ...